Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Douglas Zipes MD
Douglas P. Zipes MD Editor-in-Chief
Peter Libby MD
Peter Libby MD Advisory Board
Benjamin Scirica MD
Benjamin Morgan Scirica MD Associate Editor
See All Experts
featured
Published in Cardiology

Journal Scan / Research · July 16, 2024

Effect of Semaglutide on NT-proBNP Levels in Patients With Obesity-Related HFpEF

Journal of the American College of Cardiology

 

 Save  Recommend
 Share

Additional Info

Journal of the American College of Cardiology
Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program
J Am Coll Cardiol 2024 Jul 02;84(1)27-40, MC Petrie, BA Borlaug, J Butler, MJ Davies, DW Kitzman, SJ Shah, S Verma, TJ Jensen, MN Einfeldt, K Liisberg, E Perna, K Sharma, JA Ezekowitz, M Fu, V Melenovský, H Ito, M Lelonek, MN Kosiborod,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated